申请人:Kandula Mahesh
公开号:US20150119436A1
公开(公告)日:2015-04-30
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing blood clotting disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of strokes in those with atrial fibrillation due to causes other than heart valve disease, and at least one additional risk factor for stroke (congestive heart failure, hypertension, age, diabetes, and prior stroke), and to prevent the formation of blood clots in the veins in adults operated to replace a hip or knee.
该发明涉及公式I和公式II的化合物或其药用可接受的盐,以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I或公式II化合物的药物组合物;以及治疗或预防血液凝块性疾病的方法可能制备为口服、颊下、直肠、局部、经皮、经粘膜、静脉内、肠道、糖浆或注射。这些组合物可用于治疗由于非心脏瓣膜疾病引起的房颤患者中的中风,并且至少有一种额外的中风风险因素(充血性心力衰竭、高血压、年龄、糖尿病和先前中风),以及预防成年人在接受髋关节或膝关节置换手术后静脉形成血栓。